Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025 and declaration of 3rd Interim Dividend of Rs.1.50 per share for the fy 2025-26
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.2 pts less than Nifty Smallcap 250 and 1.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Natco Pharma reported consolidated total revenue of Rs.705.4 crore for Q3FY26, up 8.3% from Rs.651.1 crore in Q3FY25, while revenue from operations grew 36.3% YoY to Rs.647.3 crore. EBITDA for the quarter stood at Rs.216.8 crore with margins of 30.7%, and net profit was Rs.151.3 crore. For 9MFY26, consolidated revenue was Rs.3,539 crore and net profit was Rs.1,149.5 crore, a decline from Rs.1,477.4 crore in 9MFY25. The Board declared a third interim dividend of Rs.1.50 per share (75% on Rs.2 face value), with record date February 18, 2026 and payment starting February 26, 2026. Key changes include the superannuation of CFO Mr. S.V.V.N. Appa Rao, appointment of Mr. Amit Parekh as new CFO, and re-appointments of Chairman & MD and Vice Chairman & CEO. The company also completed the acquisition of 35.75% stake in Adcock Ingram Holdings (South Africa) for USD 225 million and received in-principle approval to evaluate the demerger of its Agro Chemicals business.
Short-term positive sentiment from the dividend declaration and strong Q3 revenue growth, though the 9-month profit decline may raise concerns. The Adcock acquisition and Agro Chemicals demerger evaluation could reshape the business portfolio going forward.